A Double-Blind, Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) (Triple Reuptake Inhibitor Anti-Depressant Effects - TRIADE Study).

Trial Profile

A Double-Blind, Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) (Triple Reuptake Inhibitor Anti-Depressant Effects - TRIADE Study).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Amitifadine (Primary) ; Paroxetine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms TRIADE
  • Sponsors Euthymics Bioscience
  • Most Recent Events

    • 09 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 29 May 2013 Primary endpoint 'Montgomery-Asberg-Depression-Rating-Scale' has not been met, according to a Euthymics Bioscience media release.
    • 29 May 2013 Top-line results reported in a Euthymics Bioscience media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top